Denileukin Diftitox
Denileukin Diftitox
Definition
A cytotoxic recombinant fusion protein consisting of the human cytokine interleukin-2 (IL-2) fused to diphtheria toxin fragments A and B, containing both the catalytic and translocation domains, with potential antineoplastic activity. Upon administration, the IL-2 moiety of denileukin difitox targets and binds to IL-2 receptors. After internalization by IL-2 receptor-expressing cells via endocytosis, denileukin difitox is proteolytically cleaved. This releases the catalytic domain of the toxin moiety, which catalyzes the transfer of the ADP-ribose moiety of NAD to a diphthamide residue of elongation factor 2 (EF-2). This covalent modification inactivates EF-2 and disrupts polypeptide chain elongation, resulting in an inhibition of translation and cell death.
Also known as DAB-IL2, DAB(389)-Interleukin-2, DAB(389)IL-2, DAB389 Interleukin-2, DAB389 Interleukin-2 Immunotoxin, DAB389IL-2, DAB389IL2, DABIL2, DENILEUKIN DIFTITOX, Denileukin Diftitox-cxdl, Diphtheria Toxin Fragment-Interleukin-2 Fusion Protein E7777, E7777, Interleukin-2 Fusion Protein, Interleukin-2 Fusion Toxin, LY 335348, LY-335348, LY335348, Lymphir, Ontak, Remitoro — per NCIT
Also identified as
- ATC L01XX29 per RXNORM
- NCIT NCIT:C1476 per NCIT
- SCTID 125700002 per RXNORM
- SCTID 398881002 per RXNORM
- UNII 25E79B5CTM per RXNORM
Indications
| Disease | Relation | Source |
|---|---|---|
| T-cell non-Hodgkin lymphoma | may treat | MEDRT · Public domain (U.S. Government work) |
Organ Effects
| Organ | Side effect / interaction | Source |
|---|---|---|
| Lymphoid system | may treat a disease of this organ | DERIVED · CC BY 4.0 |
1 entry above is marked DERIVED: Atlas Médico inferred it by combining two sourced claims, and no source asserts this link directly. Treat it as a navigation aid, not as a clinical statement.